Bioprocess Integrity Testing Systems

Bioprocess Integrity Testing Systems Market Outlook

The global bioprocess integrity testing systems market is projected to reach USD 3.8 billion by 2035, growing at a CAGR of 7.8% from 2025. This growth is primarily driven by the increasing demand for biopharmaceuticals and the rising adoption of advanced bioprocessing technologies across various industries. Moreover, the growing emphasis on stringent regulatory compliance and the need for high-quality processes in manufacturing environments further enhance market expansion. Technological advancements in the field of bioprocessing, such as the integration of automation and data analytics, are also expected to significantly contribute to market growth. Additionally, the rise in investments aimed at enhancing global healthcare infrastructure will propel the adoption of bioprocess integrity testing systems.

Growth Factor of the Market

The bioprocess integrity testing systems market is experiencing notable growth due to several compelling factors. The surge in biopharmaceutical production due to increased demand for biologics, including vaccines and monoclonal antibodies, is a significant driver behind this trend. Furthermore, advancements in technology, such as the introduction of automated systems that facilitate real-time monitoring and control, enhance the efficiency and reliability of bioprocessing. The growing focus on regulatory compliance within the pharmaceutical and food industries also plays a crucial role, as industries seek to meet strict guidelines while ensuring process integrity and product safety. Additionally, the rising awareness regarding product quality and safety among consumers creates a ripple effect, prompting manufacturers to prioritize robust testing systems. Finally, the expansion of bioprocessing capabilities in emerging markets is expected to further fuel the demand for bioprocess integrity testing systems.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 7.8% from 2025 to 2035.
• Biopharmaceutical applications dominate the market, driven by demand for biologics.
• Technological advancements in automation and monitoring systems are reshaping the industry.
• North America holds a significant share due to its well-established pharmaceutical sector.
• Emerging markets in Asia-Pacific are witnessing rapid growth in bioprocessing capabilities.

By Product Type

Bioreactors:

Bioreactors are critical components in the bioprocess integrity testing systems market, accounting for a substantial share due to their pivotal role in the cultivation of microorganisms and cells. They provide controlled conditions for biochemical reactions to occur, allowing for efficient production of biologics. Innovative designs and the integration of automation features have enhanced the performance and scalability of bioreactors. The increasing complexity of biopharmaceutical products necessitates advanced bioreactor systems that can maintain optimal growth conditions, leading to heightened efficiency and product yield. Additionally, the rise in personalized medicine has prompted the development of smaller, more versatile bioreactors, further driving market growth in this segment.

Filtration Systems:

Filtration systems are essential for ensuring the purity and quality of bioprocessed products. This product type encompasses various filtration techniques, including microfiltration and ultrafiltration, which are crucial for separating cells, proteins, and other particles from solutions. The growing need for sterile processes in biopharmaceutical manufacturing, along with stringent regulatory requirements, has significantly increased the demand for effective filtration systems. As biopharmaceutical companies seek to enhance process efficiency and minimize contamination risks, advanced filtration solutions are becoming indispensable. Furthermore, the development of innovative filtration technologies, such as single-use systems, is expected to propel market growth in this segment.

Centrifuges:

Centrifuges play a vital role in separating components of different densities within bioprocessing applications. They are widely used in the extraction and purification of biomolecules, such as proteins and nucleic acids, which are crucial in the biopharmaceutical industry. The effectiveness of centrifugation processes directly impacts the yield and quality of biopharmaceutical products, leading to an increasing focus on advanced centrifuge systems. The trend towards automation and integration of centrifuges into larger bioprocessing workflows enhances operational efficiencies, thereby driving the growth of this segment. Moreover, the introduction of high-throughput centrifuges that allow for faster processing times is expected to significantly contribute to market expansion.

Chromatography Systems:

Chromatography systems are essential for the purification and separation of biopharmaceutical products, playing a pivotal role in maintaining bioprocess integrity. These systems leverage various techniques, including affinity chromatography and ion exchange chromatography, to isolate specific biomolecules from complex mixtures. As the demand for high-purity products increases, the adoption of advanced chromatography technologies has surged. Innovations in chromatography, such as the development of single-use systems and continuous chromatography methods, facilitate improved efficiency and reduced processing times. As regulatory standards become more stringent, the need for reliable chromatography systems that ensure product quality will continue to drive growth in this segment.

Sensors:

Sensors are integral components of bioprocess integrity testing systems, providing real-time measurements and monitoring of critical parameters such as pH, temperature, and dissolved oxygen. The integration of advanced sensing technologies enhances the precision and reliability of bioprocessing operations, ensuring that conditions remain optimal throughout the production process. The increasing complexity of biopharmaceutical manufacturing highlights the necessity for sophisticated sensor systems that can provide accurate data for process control. Additionally, the rise of Industry 4.0 and the Internet of Things (IoT) is leading to the development of smart sensors that enable remote monitoring and predictive maintenance, further driving the demand for this product type.

By Application

Biopharmaceuticals:

Biopharmaceuticals represent a significant application segment within the bioprocess integrity testing systems market. This sector is driven by the increasing demand for biologics, including monoclonal antibodies, vaccines, and therapeutic proteins, which require stringent quality assurance measures. The rise of personalized medicine and the growing focus on biologics as treatment modalities have led to heightened scrutiny of manufacturing processes to ensure the integrity and safety of biopharmaceutical products. Advanced bioprocess integrity testing systems are crucial for detecting contaminants and ensuring compliance with regulatory standards, thereby facilitating the successful development and commercialization of biopharmaceuticals.

Biotechnology:

The biotechnology sector plays a pivotal role in driving the demand for bioprocess integrity testing systems. With the continuous advancement of biotechnology applications, including genetic engineering and cell culture, there is an increasing need for reliable testing systems to ensure process integrity. Companies in this sector are focusing on developing new bioprocessing techniques and products, which necessitate robust integrity testing systems to maintain quality control. The ongoing research and development activities in biotechnology are expected to boost the adoption of advanced testing systems, further fueling market growth in this application segment.

Food and Beverage:

The food and beverage industry has begun to recognize the significance of bioprocess integrity testing systems as part of ensuring food safety and quality. The growing consumer awareness regarding food safety, coupled with the increasing regulatory standards, has prompted food manufacturers to adopt stringent quality assurance measures. Bioprocess integrity testing systems are employed to monitor fermentation processes, assess the purity of ingredients, and ensure that products meet safety regulations. As more food and beverage companies embrace biotechnological approaches in their production processes, the demand for integrity testing systems is expected to rise, promoting market growth in this application area.

Environmental:

Environmental applications of bioprocess integrity testing systems are gaining traction as industries focus on sustainability and pollution reduction. The ability to monitor and ensure the integrity of bioprocesses involved in waste treatment and bioremediation is essential for maintaining environmental compliance. Companies are increasingly adopting bioprocess testing systems to assess the efficacy of biological treatment processes and ensure that they meet regulatory standards. The growing emphasis on sustainable practices and the use of biotechnology for environmental conservation are anticipated to drive the demand for integrity testing systems in this application segment.

By Distribution Channel

Direct Sales:

Direct sales channels have emerged as a significant mode of distributing bioprocess integrity testing systems, allowing manufacturers to establish strong relationships with customers. By selling directly, companies can provide tailored solutions and better understand client needs, ultimately improving customer satisfaction. Additionally, direct sales facilitate faster delivery and clearer communication regarding product specifications and support services. As manufacturers aim to enhance their market reach, direct sales strategies are being prioritized, fostering growth in this distribution channel. Furthermore, the ability to provide hands-on demonstrations and training sessions through direct sales is a key advantage that enhances the customer experience.

Distributor Sales:

Distributor sales continue to play a crucial role in the bioprocess integrity testing systems market, providing manufacturers with broader access to diverse customer bases. Distributors often possess established networks within specific regions and industries, allowing for effective penetration into new markets. They can leverage their expertise and relationships to promote bioprocess integrity testing systems among potential clients. Moreover, distributors can offer additional value through logistical support, technical assistance, and after-sales services, which help build brand loyalty. As the market expands, the reliance on distributor sales is expected to remain strong, particularly in regions with emerging biopharmaceutical industries.

Online Retailers:

The rise of online retailing has revolutionized the way bioprocess integrity testing systems are marketed and sold. E-commerce platforms provide manufacturers with a cost-effective channel to reach global customers, enabling them to showcase their products to a broader audience. The convenience of online purchasing has led to increased accessibility and consumer preference for online transactions. Furthermore, online retailers often provide valuable resources, such as product comparisons and customer reviews, which aid in informed purchasing decisions. As digital transformation continues to reshape the bioprocessing landscape, the significance of online retailers in the market is anticipated to grow, fostering innovation and competition.

By Technology Type

Microfiltration:

Microfiltration technology plays a significant role in bioprocess integrity testing systems, primarily due to its ability to remove contaminants and particles from various solutions. This technology is widely utilized in the biopharmaceutical industry for the clarification and sterilization of biological liquids, ensuring the integrity of the final product. The demand for microfiltration systems is driven by the need for high-quality end products and stringent regulatory requirements. Additionally, advancements in membrane technology have enhanced the efficiency and effectiveness of microfiltration processes, thereby promoting the adoption of this technology across various applications within the bioprocessing sector.

Ultrafiltration:

Ultrafiltration is another critical technology type within the bioprocess integrity testing systems market, particularly valued for its role in separating molecules based on size. This technology is essential for concentrating and purifying proteins, enzymes, and other biomolecules in biopharmaceutical production. The increasing focus on bioprocess optimization and the need for high-purity products have driven the demand for ultrafiltration systems. Additionally, the development of advanced ultrafiltration membranes with improved performance characteristics enhances operational efficiencies, promoting market growth. As biopharmaceutical processes evolve, ultrafiltration technology remains fundamental in ensuring product integrity and quality.

Reverse Osmosis:

Reverse osmosis technology is vital for the removal of dissolved salts and other contaminants from water and solutions, making it indispensable in bioprocess integrity testing systems. This technology ensures that the water used in bioprocessing meets the stringent quality standards required by various industries. The growing emphasis on water quality and sustainable practices drives the demand for reverse osmosis systems in the biopharmaceutical and food industries. Moreover, ongoing advancements in reverse osmosis membrane technology enhance efficiency and reduce operational costs, further propelling market growth. As industries prioritize water purification processes, reverse osmosis technology will continue to play a crucial role in maintaining bioprocess integrity.

Chromatography:

Chromatography technology is a cornerstone in the bioprocess integrity testing systems market, primarily used for the separation and purification of biomolecules. Techniques such as ion exchange chromatography and affinity chromatography are critical in ensuring the quality and integrity of biopharmaceutical products. Demand for advanced chromatography systems is driven by the increasing complexity of biologics and the need for high-purity products. The evolution of chromatography technologies, including the introduction of continuous chromatography and single-use systems, enhances efficiency and minimizes cross-contamination risks. As biopharmaceutical manufacturers strive for improved process performance, chromatography technology will remain integral in maintaining bioprocess integrity.

Spectrophotometry:

Spectrophotometry technology is essential for measuring the absorbance and transmission of light through solutions, enabling qualitative and quantitative analysis of biomolecules. This technology plays a significant role in bioprocess integrity testing, particularly in assessing the concentration and purity of various substances in biopharmaceutical production. The growing demand for quality control and process monitoring has led to increased adoption of spectrophotometric techniques. Furthermore, advancements in spectrophotometry, such as the integration of automation and data analytics, improve operational efficiencies and accuracy in testing. As industries prioritize process integrity, spectrophotometry will continue to be a valuable tool for maintaining high-quality standards in bioprocessing.

By Region

In the North American region, the bioprocess integrity testing systems market is poised to experience substantial growth, primarily due to the presence of a robust biopharmaceutical industry and favorable regulatory frameworks. The region's well-established healthcare infrastructure, combined with significant investments in biotechnology research and development, drives the demand for advanced testing systems. The market in North America is projected to grow at a CAGR of 8.2% from 2025 to 2035, as companies seek to enhance product quality and meet stringent regulatory compliance. Additionally, the increasing focus on biologics and personalized medicine further contributes to the expansion of the bioprocess integrity testing systems market in this region.

In Europe, the bioprocess integrity testing systems market is also witnessing significant growth, fueled by the increasing demand for biopharmaceuticals and the adoption of innovative bioprocessing technologies. The European market is anticipated to experience steady expansion as companies aim to improve manufacturing efficiency and ensure product safety. The emphasis on sustainability and environmental compliance within the bioprocessing sector is also driving the adoption of integrity testing systems. Furthermore, with countries like Germany, the UK, and France leading the way in biopharmaceutical development, Europe is expected to remain a key player in the global market, contributing to a sizeable share of overall revenue.

Opportunities

The bioprocess integrity testing systems market presents numerous opportunities for growth, particularly as industries increasingly recognize the importance of maintaining high-quality standards. One significant opportunity lies in the rapid advancement of automation and data analytics technologies that enhance operational efficiencies. By integrating smart technologies into bioprocessing workflows, companies can improve monitoring capabilities, reduce human error, and optimize production processes. Additionally, the growing trend towards personalized medicine and biologics creates a substantial demand for advanced testing systems that ensure product quality and safety. This evolving landscape presents attractive prospects for manufacturers looking to innovate and provide cutting-edge solutions to meet industry demands.

Another valuable opportunity in the market is the expansion of bioprocessing capabilities in emerging economies. As countries in Asia-Pacific and Latin America invest in their healthcare infrastructures and biopharmaceutical industries, the demand for bioprocess integrity testing systems is expected to rise. This trend is driven by the need to meet global quality standards and the increasing production of biologics in these regions. Furthermore, collaborations and partnerships between established players and local companies can facilitate the introduction of advanced testing systems in emerging markets, promoting growth and enhancing competitive positioning. As these opportunities unfold, industry stakeholders are well-positioned to capitalize on the expanding global market for bioprocess integrity testing systems.

Threats

Despite the promising growth prospects, the bioprocess integrity testing systems market faces several threats that could hinder its expansion. One significant threat is the intense competition among established players and new entrants, leading to pricing pressures and potential erosion of profit margins. As companies strive to differentiate their offerings, the race for innovation and technological advancements may result in substantial investments in research and development, which can strain financial resources. Additionally, regulatory hurdles and compliance requirements can pose challenges for manufacturers seeking to enter new markets or launch new products. The evolving nature of regulations demands continuous monitoring and adaptation, which can be resource-intensive and inhibit market growth.

Moreover, the potential for economic downturns and fluctuations in healthcare spending can create uncertainties in the bioprocess integrity testing systems market. During challenging economic conditions, companies may prioritize cost-cutting measures, leading to reduced investments in bioprocessing technologies and testing systems. This could slow down the adoption of new solutions and hinder overall market growth. Another concern involves the rapid pace of technological advancements, which may render existing systems obsolete if companies do not keep pace with innovations. To navigate these threats, industry stakeholders must remain agile and responsive to changing market dynamics, ensuring they can adapt to challenges while capitalizing on growth opportunities.

Competitor Outlook

• GE Healthcare
• Pall Corporation
• Merck Millipore
• Thermo Fisher Scientific
• Sartorius AG
• Danaher Corporation
• Waters Corporation
• Novasep
• Eppendorf AG
• Tecan Group
• 3M Company
• Filtration Group Corporation
• GVS Filter Technology
• Repligen Corporation
• Koch Membrane Systems

The competitive landscape of the bioprocess integrity testing systems market is characterized by a mix of established and emerging players, each vying for market share through innovation and strategic positioning. In recent years, leading companies have focused on expanding their product portfolios and investing in advanced technologies to meet the evolving demands of customers. Strategic collaborations, mergers, and acquisitions have also become prominent strategies among key players, enabling them to strengthen their market presence and leverage synergies. The emphasis on research and development remains crucial as companies seek to enhance their offerings and introduce cutting-edge solutions that cater to specific industry needs.

GE Healthcare is a prominent player in the bioprocess integrity testing systems market, offering a wide range of products including bioreactors and filtration systems. The company is known for its innovative approach, focusing on automation and digital solutions to enhance bioprocessing efficiencies. Another key player, Pall Corporation, specializes in filtration and separation technologies, providing critical solutions for biopharmaceutical manufacturing. Their emphasis on quality and compliance has positioned them as a trusted partner in the industry. Sartorius AG is also noteworthy, offering an extensive portfolio of solutions tailored for bioprocessing applications, emphasizing the importance of sustainability and efficiency in their systems.

Moreover, Thermo Fisher Scientific and Merck Millipore are recognized leaders in the bioprocess integrity testing systems market, known for their robust product lines and continuous innovation. Both companies invest significantly in research and development to stay ahead of technological advancements and regulatory changes. Waters Corporation, with its state-of-the-art chromatography systems, caters to the needs of biopharmaceutical manufacturers looking for high-purity products. Additionally, emerging companies like Repligen Corporation are gaining traction by focusing on specialized bioprocessing solutions, offering unique technologies that address specific market needs. As the competitive landscape continues to evolve, the focus on customer-centric solutions and technological innovation will remain key drivers of success in the bioprocess integrity testing systems market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Novasep
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 3M Company
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Tecan Group
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Eppendorf AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sartorius AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 GE Healthcare
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck Millipore
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pall Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Waters Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Danaher Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Repligen Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GVS Filter Technology
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Koch Membrane Systems
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Filtration Group Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Bioprocess Integrity Testing Systems Market, By Application
    • 6.1.1 Biopharmaceuticals
    • 6.1.2 Biotechnology
    • 6.1.3 Food and Beverage
    • 6.1.4 Environmental
  • 6.2 Bioprocess Integrity Testing Systems Market, By Product Type
    • 6.2.1 Bioreactors
    • 6.2.2 Filtration Systems
    • 6.2.3 Centrifuges
    • 6.2.4 Chromatography Systems
    • 6.2.5 Sensors
  • 6.3 Bioprocess Integrity Testing Systems Market, By Technology Type
    • 6.3.1 Microfiltration
    • 6.3.2 Ultrafiltration
    • 6.3.3 Reverse Osmosis
    • 6.3.4 Chromatography
    • 6.3.5 Spectrophotometry
  • 6.4 Bioprocess Integrity Testing Systems Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales
    • 6.4.3 Online Retailers

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Bioprocess Integrity Testing Systems Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Bioprocess Integrity Testing Systems market is categorized based on

By Product Type

• Bioreactors
• Filtration Systems
• Centrifuges
• Chromatography Systems
• Sensors

By Application

• Biopharmaceuticals
• Biotechnology
• Food and Beverage
• Environmental

By Distribution Channel

• Direct Sales
• Distributor Sales
• Online Retailers

By Technology Type

• Microfiltration
• Ultrafiltration
• Reverse Osmosis
• Chromatography
• Spectrophotometry

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Pall Corporation
• Merck Millipore
• Thermo Fisher Scientific
• Sartorius AG
• Danaher Corporation
• Waters Corporation
• Novasep
• Eppendorf AG
• Tecan Group
• 3M Company
• Filtration Group Corporation
• GVS Filter Technology
• Repligen Corporation
• Koch Membrane Systems